323990.KQ KOE
Vaxcell-Bio Therapeutics Co., Ltd.
1W: +1.8%
1M: -15.5%
3M: -12.2%
YTD: -58.0%
1Y: -54.3%
3Y: -86.2%
5Y: -94.3%
₩4,285.00 ($3.19)
-25.00 (-0.58%)
Weekly Expected Move ±7.6%
₩3630
₩3958
₩4285
₩4612
₩4940
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$10.6B
+0.7% ▲
Capital Expenditures
$6.0B
-48.7% ▼
5Y CAGR: +185.4%
Free Cash Flow
-$16.7B
-12.9% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$1.6B
-30.4% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$4.8B | -$6.8B | -$10.3B | -$10.6B | -$13.3B |
| Depreciation & Amort. | $257M | $311M | $400M | $1.5B | $2.2B |
| Stock-Based Comp. | $47M | $38M | $182M | $209M | $0 |
| Change in Working Capital | -$554M | -$283M | -$233M | -$1.7B | -$2.0B |
| Other Non-Cash Items | $89M | $157K | $503M | -$15M | $2.5B |
| Operating Cash Flow | -$4.7B | -$6.0B | -$9.4B | -$10.7B | -$10.6B |
| — Investing Activities — | |||||
| Capital Expenditures | -$2.2B | -$290M | -$199M | -$2.1B | -$6.8B |
| Acquisitions (Net) | $0 | $0 | $0 | -$4.8B | -$404M |
| Investment Purchases | -$15.3B | -$23.0B | -$92.3B | -$21.9B | -$42.4B |
| Investment Sales | $14.3B | $28.0B | $41.3B | $41.4B | $59.7B |
| Other Investing | -$9M | -$374M | -$591M | -$2.2B | $232M |
| Investing Cash Flow | -$3.2B | $4.3B | -$51.8B | $10.3B | $10.4B |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $0 | $0 | $0 | -$300M |
| Stock Repurchased | $0 | $0 | -$533M | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$293M | -$208M | -$1.4B | -$849M | -$1.0B |
| Financing Cash Flow | $305M | -$208M | $69.9B | -$849M | -$1.3B |
| Net Change in Cash | -$7.6B | -$1.9B | $8.7B | -$1.2B | -$1.6B |
| Cash End of Period | $2.3B | $390M | $9.0B | $7.8B | $6.2B |
| Free Cash Flow | -$6.9B | -$6.3B | -$9.6B | -$14.8B | -$16.7B |